CWF19L1: Potential Drug Target Or Biomarker for Cancer (G55280)

Target Name: CWF19L1

NCBI ID: G55280

CWF19L1

CWF19L1: Potential Drug Target Or Biomarker for Cancer

CWF19L1, also known as human Dbr1 associated ribonuclease 1, is a protein that is expressed in various tissues throughout the body. It plays a critical role in the process of DNA damage repair, which is a crucial mechanism for maintaining cellular health. Unfortunately, diseases such as cancer can cause damage to the DNA, leading to the development of cancer. Therefore, research on CWF19L1 and its potential as a drug target or biomarker has gained significant attention in recent years.

CWF19L1 is a member of the nucleotide-binding oligomerization domain family (NBD), which is a group of proteins that play a crucial role in various cellular processes, including DNA damage repair, gene expression, and cell signaling. NBD proteins are characterized by a specific domain that allows them to interact with specific nucleotides. In the case of CWF19L1, the NBD domain interacts with G-C pairs in the double helix, which is critical for DNA damage repair.

One of the key functions of CWF19L1 is its role in DNA damage repair. DNA damage can occur due to various factors, such as radiation, chemical agents, or errors in DNA replication. These damages can cause the cell to enter a state of stress, which can lead to the development of diseases such as cancer. CWF19L1 plays a critical role in repairing these damages by interacting with the double helix and ensuring the proper execution of DNA repair processes.

CWF19L1 has also been shown to be a potential drug target in cancer treatment. Cancer cells are known to have altered levels of CWF19L1, which allows them to evade the effects of cancer treatments. Therefore, targeting CWF19L1 with drugs could be an effective way to treat cancer. Several studies have shown that inhibiting CWF19L1 activity can lead to the growth inhibition of cancer cells.

Another promising aspect of CWF19L1 is its potential as a biomarker for cancer diagnosis. The expression of CWF19L1 has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. Therefore, using CWF19L1 as a biomarker for cancer diagnosis could be an effective way to identify the type of cancer a patient has.

CWF19L1 is also a potential biomarker for monitoring the effectiveness of cancer treatments. The expression of CWF19L1 has been shown to be decreased following treatment with certain chemotherapy drugs, which suggests that these drugs may be effective in reducing the levels of CWF19L1 in cancer cells. Therefore, measuring the levels of CWF19L1 after cancer treatment could be an effective way to monitor the effectiveness of these treatments.

In conclusion, CWF19L1 is a protein that plays a critical role in various cellular processes, including DNA damage repair and cancer diagnosis. Its potential as a drug target or biomarker has gained significant attention in recent years. The expression of CWF19L1 has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. Therefore, targeting CWF19L1 with drugs or using it as a biomarker for cancer diagnosis and treatment could be an effective way to improve cancer treatment outcomes.

Protein Name: CWF19 Like Cell Cycle Control Factor 1

The "CWF19L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CWF19L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets